Please assess the completion status of the following clinical trial:

Trial Title: Effect of Branched-chain Amino Acids (BCAA) to Muscle Cramps in Patients With Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Muscle cramp ≥ 1 time per week~* Confirmed cirrhotic status (radiologic finding compatible with cirrhosis or liver stiffness measurement ≥ 12.5 kPa by transient elastography method or pathological confirm of cirrhosis)~Exclusion Criteria:~* Allergy to BCAA~* Overt hepatic encephalopathy~* Hepatorenal syndrome~* Severe renal insufficiency; eGFR \< 30~* Heart failure~* Peripheral arterial disease~* Active malignancies beyond hepatocellular carcinoma~* Heavy alcohol drinking (\> 21g/day for men and \>14g/day for women)~* Pregnancy or lactation~* Current use of BCAA within 3 months~* Recent adding or titrating diuretics within 4 weeks~* On current medications for muscle cramp relief such as vitamin E, taurine, carnitine, narcotic pain medications, baclofen, methocarbamol, other muscle relaxers, NSAIDs, or other antispastic agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- BCAA group (Type: ACTIVE_COMPARATOR): 12.45 grams of branched-chain amino acids orally per day before bedtime for 12 weeks.
- Placebo group (Type: PLACEBO_COMPARATOR): 12.45 grams of placebo (Maltodextrin) orally per day before bedtime for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).